Geoffrey A. Weinberg
YOU?
Author Swipe
View article: Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments
Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments Open
Importance Despite national recommendations, antiviral prescribing in emergency departments (EDs) for children at higher risk of severe influenza, such as those younger than 5 years and those with specific underlying conditions, remains lo…
View article: Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024
Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024 Open
Importance Studies of COVID-19, influenza, and respiratory syncytial virus (RSV) disease clinical epidemiology, disease burden, and vaccine effectiveness often rely on clinical testing to identify cases, particularly with increasing use of…
View article: Genomic Analysis of Rotavirus G8P[8] Strains Detected in the United States Through Active Surveillance, 2016–2017
Genomic Analysis of Rotavirus G8P[8] Strains Detected in the United States Through Active Surveillance, 2016–2017 Open
G8 rotaviruses are primarily associated with animals and infrequently cause infections in humans. The first detection of G8 strains in humans occurred around 1979, and since then, their presence has been sporadic, particularly in the Unite…
View article: Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis
Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis Open
BACKGROUND Human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are genetically related viruses and major causes of medically attended acute respiratory illness in children. Research comparing the severity of illnesses result…
View article: Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016–2020
Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016–2020 Open
Background Influenza contributes to a high burden of pediatric emergency department (ED) visits annually. Guidelines recommend outpatient antiviral treatment for children at higher risk of severe influenza and recommend considering treatme…
View article: Enterovirus D68–Associated Respiratory Illness in Children
Enterovirus D68–Associated Respiratory Illness in Children Open
Importance Enterovirus D68 (EV-D68) typically causes mild to severe acute respiratory illness (ARI). Testing and surveillance for EV-D68 in the US are limited, and important epidemiologic gaps remain. Objective To characterize the epidemio…
View article: Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 Open
Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody for infants aged 0-7 months and children aged 8-19 months who are at increased risk for severe RSV disease, became widely available for pr…
View article: None: Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences
None: Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences Open
View article: Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences
Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences Open
Introduction Rotavirus vaccine evaluations have noted small differences in vaccine effectiveness (VE) against rotavirus genotypes, defined by the two outer capsid proteins (VP7 or G-type and VP4 or P-type). However, the genomic landscape o…
View article: Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences
Estimation of Rotavirus Vaccine Effectiveness Based on Whole Genome Sequences Open
Introduction Rotavirus vaccine evaluations have noted small differences in vaccine effectiveness (VE) against rotavirus genotypes, defined by the two outer capsid proteins (VP7 or G-type and VP4 or P-type). However, the genomic landscape o…
View article: Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025
Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025 Open
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hos…
View article: P-670. Differences in Adenovirus Type Detection in Children with Acute Respiratory Illness versus Healthy Controls: New Vaccine Surveillance Network (NVSN) 2016-2019
P-670. Differences in Adenovirus Type Detection in Children with Acute Respiratory Illness versus Healthy Controls: New Vaccine Surveillance Network (NVSN) 2016-2019 Open
Background Human adenovirus (HAdV) is a common cause of acute respiratory illness (ARI) in children, ranging from asymptomatic to life-threatening disease. While previous studies have examined asymptomatic vs HAdV ARI infections, few have …
View article: P-2366. Influenza-Specific Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic, New Vaccine Surveillance Network (2016–2023)
P-2366. Influenza-Specific Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic, New Vaccine Surveillance Network (2016–2023) Open
Background Influenza-specific antivirals are recommended for all hospitalized children with suspected or confirmed influenza. However, antiviral use remains suboptimal. We investigated antiviral use in children hospitalized with influenza …
View article: P-1203. Acute Respiratory Viral Infections in Children with Malignancy in the CDC New Vaccine Surveillance Network, 2016–2020
P-1203. Acute Respiratory Viral Infections in Children with Malignancy in the CDC New Vaccine Surveillance Network, 2016–2020 Open
Background Acute respiratory infections (ARI) can be severe in children with malignancy. We studied the frequency of respiratory viruses in children with cancer (leukemia, lymphoma, solid organ, or CNS) who presented with ARI in the CDC Ne…
View article: P-2329. Diversity of Rhinovirus Types in Children During the COVID-19 Pandemic, New Vaccine Surveillance Network, 03/01/20-02/28/21
P-2329. Diversity of Rhinovirus Types in Children During the COVID-19 Pandemic, New Vaccine Surveillance Network, 03/01/20-02/28/21 Open
Background During the COVID-19 pandemic, seasonal respiratory virus detections decreased. However, rhinoviruses (RV) continued to circulate in high numbers. Previous data suggest that RV type circulation is heterogenous and diverse. We cha…
View article: P-1209. Changes in Antiviral Prescription for Children with Influenza in U.S. Emergency Departments During the COVID-19 Pandemic: New Vaccine Surveillance Network (NVSN), 2016-2023
P-1209. Changes in Antiviral Prescription for Children with Influenza in U.S. Emergency Departments During the COVID-19 Pandemic: New Vaccine Surveillance Network (NVSN), 2016-2023 Open
Background Despite recommendations from CDC and ACIP, antiviral prescription for children who are at higher risk of severe influenza (including those < 5 years and those with certain underlying conditions) in emergency departments (EDs)…
View article: P-2358. Viral etiologies of bronchiolitis, pneumonia, and croup in children less than 5 years old, New Vaccine Surveillance Network, 2016-2022
P-2358. Viral etiologies of bronchiolitis, pneumonia, and croup in children less than 5 years old, New Vaccine Surveillance Network, 2016-2022 Open
Background Acute respiratory illness (ARI) is a leading cause of medically attended visits among children. A multi-season, multicenter, prospective evaluation of viral etiologies for different ARI syndromes is lacking. We describe the epid…
View article: Estimated Vaccine Effectiveness for Pediatric Patients With Severe Influenza, 2015-2020
Estimated Vaccine Effectiveness for Pediatric Patients With Severe Influenza, 2015-2020 Open
Importance Increasing the understanding of vaccine effectiveness (VE) against levels of severe influenza in children could help increase uptake of influenza vaccination and strengthen vaccine policies globally. Objective To investigate VE …
View article: Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study Open
Background Guidelines state that all hospitalized children with suspected or confirmed influenza receive prompt treatment with influenza-specific antivirals. We sought to determine the frequency of, and factors associated with, antiviral r…
View article: Underutilization of Influenza Antiviral Treatment Among Children and Adolescents at Higher Risk for Influenza-Associated Complications — United States, 2023–2024
Underutilization of Influenza Antiviral Treatment Among Children and Adolescents at Higher Risk for Influenza-Associated Complications — United States, 2023–2024 Open
Annually, tens of thousands of U.S. children and adolescents are hospitalized with seasonal influenza virus infection. Both influenza vaccination and early initiation of antiviral treatment can reduce complications of influenza. Using data…
View article: Pediatric Clinical Influenza Disease by Type and Subtype 2015–2020: A Multicenter, Prospective Study
Pediatric Clinical Influenza Disease by Type and Subtype 2015–2020: A Multicenter, Prospective Study Open
Background Previous investigations into clinical signs and symptoms associated with influenza types and subtypes have not definitively established differences in the clinical presentation or severity of influenza disease. Methods The study…
View article: Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022
Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022 Open
BACKGROUND Rotavirus was the leading cause of acute gastroenteritis among US children until vaccine introduction in 2006, after which, substantial declines in severe rotavirus disease occurred. We evaluated rotavirus vaccine effectiveness …
View article: Evaluation of a Modified Vesikari Severity Score as a Research Tool for Assessing Pediatric Acute Gastroenteritis
Evaluation of a Modified Vesikari Severity Score as a Research Tool for Assessing Pediatric Acute Gastroenteritis Open
A modified Vesikari severity score (MVSS) is a useful research tool for assessing severity of acute gastroenteritis. We present a MVSS for studies in which a follow-up assessment of symptoms cannot be obtained. The MVSS significantly corre…
View article: Influenza C virus in U.S. children with acute respiratory infection 2016–2019
Influenza C virus in U.S. children with acute respiratory infection 2016–2019 Open
Influenza C virus (ICV) is an orthomyxovirus related to influenza A and B, yet due to few commercial assays, epidemiologic studies may underestimate incidence of ICV infection and disease. We describe the epidemiology and characteristics o…
View article: Accuracy of Influenza <i>ICD-10</i> Diagnosis Codes in Identifying Influenza Illness in Children
Accuracy of Influenza <i>ICD-10</i> Diagnosis Codes in Identifying Influenza Illness in Children Open
Importance Studies of influenza in children commonly rely on coded diagnoses, yet the ability of International Classification of Diseases, Ninth Revision codes to identify influenza in the emergency department (ED) and hospital is highly v…
View article: Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 Open
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for…
View article: Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States Open
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patien…
View article: <i>Notes from the Field:</i>Reemergence of<i>Mycoplasma pneumoniae</i>Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024
<i>Notes from the Field:</i>Reemergence of<i>Mycoplasma pneumoniae</i>Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 Open
View article: Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged &lt;5 Years: New Vaccine Surveillance Network, United States, 2016–2020
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016–2020 Open
Background Respiratory syncytial virus (RSV) is a leading cause of acute respiratory illnesses in children. RSV can be broadly categorized into 2 major subtypes: A and B. RSV subtypes have been known to cocirculate with variability in diff…
View article: Effectiveness of Maternal Influenza Vaccination During Pregnancy Against Influenza-Associated Emergency Department Visits and Hospitalizations in Infants <6 Months of Age
Effectiveness of Maternal Influenza Vaccination During Pregnancy Against Influenza-Associated Emergency Department Visits and Hospitalizations in Infants <6 Months of Age Open